Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734–47. https://doi.org/10.1056/NEJMra1402225.

Article  PubMed  Google Scholar 

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64. https://doi.org/10.1136/annrheumdis-2017-211468.

Article  PubMed  Google Scholar 

Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7:86. https://doi.org/10.1038/s41572-021-00321-x.

Article  PubMed  Google Scholar 

Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14:255–68. https://doi.org/10.1038/nrrheum.2018.48.5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64:3736–40. https://doi.org/10.1002/art.34657.

Article  CAS  PubMed  Google Scholar 

Chen Z, Wang Y, Kuwana M, Xu X, Hu W, Feng X, et al. HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis. J Rheumatol. 2017;44:1389–93. https://doi.org/10.3899/jrheum.170165.

Article  CAS  PubMed  Google Scholar 

Nguyen Thi Phuong T, Nguyen Thi Ngoc L, Nguyen Xuan H, Rönnelid J, Padyukov L, Lundberg IE. Clinical phenotype, autoantibody profile and HLA-DR-type in Vietnamese patients with idiopathic inflammatory myopathies. Rheumatology. 2019;58:361–3. https://doi.org/10.1093/rheumatology/key313.

Article  CAS  PubMed  Google Scholar 

O’Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine. 2006;85:111–27. https://doi.org/10.1097/01.md.0000217525.82287.eb.

Article  CAS  PubMed  Google Scholar 

O’Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 2006;54:3670–81. https://doi.org/10.1002/art.22205.

Article  CAS  PubMed  Google Scholar 

Furuya T, Hakoda M, Higami K, Ueda H, Tsuchiya N, Tokunaga K, et al. Association of HLA class I and class II alleles with myositis in Japanese patients. J Rheumatol. 1998;25:1109–14.

CAS  PubMed  Google Scholar 

Che WI, Lundberg IE, Holmqvist M. Environmental risks for Inflammatory myopathies. Rheum Dis Clin North Am. 2022;48:861–74. https://doi.org/10.1016/j.rdc.2022.06.007.

Article  PubMed  Google Scholar 

Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021;23:63. https://doi.org/10.1007/s11926-021-01023-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saygin D, Ghosh N, Reid P. Immune checkpoint inhibitor–associated myositis. J Clin Rheumatol. 2022;28:367–73. https://doi.org/10.1097/RHU.0000000000001874.

Article  PubMed  Google Scholar 

Kouranloo K, Dey M, Elwell H, Nune A. A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19. Rheumatol Int. 2023;43:1–23. https://doi.org/10.1007/s00296-023-05283-9.

Article  Google Scholar 

Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10:3592. https://doi.org/10.3390/cells10123592.16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang K-T, Hsu B-C, Chen D-Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12:645013. https://doi.org/10.3389/fimmu.2021.645013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, NorooziFarhadi P, et al. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology. 2022;61:SI143-50. https://doi.org/10.1093/rheumatology/keac249.18.

Article  PubMed  PubMed Central  Google Scholar 

Xie Y, Liu Y, Liu Y. The flare of rheumatic disease after SARS-CoV-2 vaccination: a review. Front Immunol. 2022;13:919979. https://doi.org/10.3389/fimmu.2022.919979.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Xu Z, Wang P, Li X-M, Shuai Z-W, Ye D-Q, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunol. 2022;165:386–401. https://doi.org/10.1111/imm.13443.

Article  CAS  Google Scholar 

Guo M, Liu X, Chen X, Li Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun Rev. 2023;22:103340. https://doi.org/10.1016/j.autrev.2023.103340.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kharouf F, Kenig A, Bohbot E, Rubin L, Peleg H, Shamriz O. Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience. Clin Exp Rheumatol. 2023;41:316–21. https://doi.org/10.55563/clinexprheumatol/970881.

Article  PubMed  Google Scholar 

Holzer M-T, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int. 2022;42:2267–76. https://doi.org/10.1007/s00296-022-05176-3.23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12:5417. https://doi.org/10.1038/s41467-021-25509-3. This longitudinal analysis of prototypical autoantibodies associated with SAIRDs in hospitalized COVID-19 patients found that a subset of autoantibodies developed de novo following SARS-CoV-2 infection.

Teo K-F, Chen D-Y, Hsu J-T, Lai Y-H, Chang C-K, Hsueh P-R, et al. Screening and characterization of myositis-related autoantibodies in COVID-19 patients. Clin Transl Sci. 2023;16:140–50. https://doi.org/10.1111/cts.13434.

Article  CAS  PubMed  Google Scholar 

Swartzman I, Gu JJ, Toner Z, Grover R, Suresh L, Ullman LE. Prevalence of myositis-specific autoantibodies and myositis-associated autoantibodies in COVID-19 patients: a pilot study and literature review. Cureus. 2022;14:e29752. https://doi.org/10.7759/cureus.29752.

Article  PubMed  PubMed Central  Google Scholar 

Rebendenne A, Valadão ALC, Tauziet M, Maarifi G, Bonaventure B, McKellar J, et al. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J Virol. 2021;95:e02415-e2420. https://doi.org/10.1128/JVI.02415-20.

Article  CAS  PubMed  Google Scholar 

Yin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, Yamamoto Y, et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 2021;34:108628. https://doi.org/10.1016/j.celrep.2020.108628.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu H, Yang H, Liu Y, Yan B. Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system. Front Med. 2021;8:833114. https://doi.org/10.3389/fmed.2021.833114.

Article  Google Scholar 

Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. 2020;56:2001618. https://doi.org/10.1183/13993003.01618-2020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Du G, Zhang G, Matucci-Cerinic M, Furst DE. Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Ann Rheum Dis. 2022;81:e192. https://doi.org/10.1136/annrheumdis-2020-218594. This short review summarized cinical and pathological similarities and differences between severe COVID-19 pneumonia and anti-MDA5 antibody-positive DM-associated rapidly-progressive ILD.

Kondo Y, Kaneko Y, Takei H, Tamai H, Kabata H, Suhara T, et al. COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still’s disease. Clin Exp Rheumatol. 2021;39:631–8. https://doi.org/10.55563/clinexprheumatol/44kaji.

Article  PubMed  Google Scholar 

Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity. 2020;53:19–25. https://doi.org/10.1016/j.immuni.2020.06.017.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology. 2014;53:2196–203. https://doi.org/10.1093/rheumatology/keu258.

Article  CAS  PubMed  Google Scholar 

Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371:507–18. https://doi.org/10.1056/NEJMoa1312625.

Article  CAS  PubM